So first the “less good” news … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer | Tagged: OPKO, point of care, PSA, Sangia, test | 6 Comments »
-
-
-
-
-
-
- The "New" Prostate Cancer InfoLink has been developed to become a primary source of accurate, current, and topical information about prostate cancer for patients and their families.
A service of
Awards
Other PCI web sites
-
Disclaimer
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
-
Hot Posts …
- Xofigo 2.0
- Another new urine test for risk of prostate cancer
- Lu-177-PSMA-617 vs Jevtana (cabazitaxel): which should I do next?
- AS and management of Grade Group 2 prostate cancer
- Risk for and detection of clinically significant prostate cancer in previously unbiopsied patients
- ADT and risk for COVID-19 infection?
- Avoiding radiation damage to salivary glands with Ac-225-PSMA-617 therapy
- “Dose painting”: simultaneous integrated boost to the dominant intraprostatic lesion
- SBRT for high-risk prostate cancer patients
- Urine testing for risk of prostate cancer: a current and future perspective
- Mediterranean diet, active surveillance, and low-risk prostate cancer: the details
- Mediterranean diet, active surveillance, and low-risk prostate cancer
- Whole pelvic salvage radiation may be better than precisely targeted lymph node salvage radiation
- FDA approves first, oral LHRH antagonist
- Targeting bone metastases with radiation in oligorecurrent men has no survival benefit in Mayo study
… and Archives
Blog at WordPress.com. WP Designer.
